← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity
HomeStocksLBRXRevenue History
OverviewPriceRevenueEarningsP/ERatiosDividendTargets

LBRX logoLB Pharmaceuticals Inc Common Stock (LBRX) Revenue History

Annual and quarterly revenue from 2022 to 2024

TTM Revenue
$0
0
YoY Growth
-
Latest Quarter
$0
Q3 2025
QoQ Growth
-

Compound Annual Growth Rate (CAGR)

3-Year-
5-Year-
10-Year-
Highest Annual Revenue$0 (0)
Highest Quarter$0 ()

Loading revenue history...

LBRX Revenue Growth

1-Year Growth
-
3-Year CAGR
-
5-Year CAGR
-
10-Year CAGR
-
TTM vs Prior Year-
Peak Annual Revenue$0 (0)

Download Historical Data

3 records • Includes OHLCV + Technical Indicators (MA50, MA200, RSI)

Free sign in required to download data

LBRX Revenue Analysis (2022–2024)

As of May 8, 2026, LB Pharmaceuticals Inc Common Stock (LBRX) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q3 2025) recorded $0 in revenue.

Looking at the longer-term picture, LBRX's historical revenue data shows various trends over time.

When compared to Healthcare sector peers including INVA (+13.6% YoY), ACAD (+9.9% YoY), and AXSM (+63.9% YoY). Compare LBRX vs INVA →

LBRX Revenue vs Peers

Revenue metrics vs comparable public companies

CompanyTTM RevenueYoY Growth5Y CAGROp. MarginCompare
LBRX logoLBRXCurrent$0---
INVA logoINVA$425M+13.6%+4.8%38.5%
ACAD logoACAD$1.1B+9.9%+19.4%9.8%
AXSM logoAXSM$638M+63.9%--26.5%
Best in groupLowest in group

LBRX Historical Revenue Data (2022–2024)

Showing 3 of 3 records
Year Revenue YoY % Gross Profit Gross Margin Op. Income Op. Margin
2024$0-$0-$-64,830,000-
2023$0-$0-$-11,376,000-
2022$0-$0-$-2,809,000-

See LBRX's True Return

Price is only half the story. See total return with reinvested dividends.

Launch Calculator

Is LBRX Undervalued?

DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.

View Valuation

Compare LBRX vs DBVT

Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..

Start Comparison

LBRX — Frequently Asked Questions

Quick answers to the most common questions about buying LBRX stock.

Is LBRX's revenue growth accelerating or slowing?

LBRX TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.

What is LBRX's long-term revenue growth rate?

LB Pharmaceuticals Inc Common Stock's 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.

How is LBRX's revenue distributed by segment?

LBRX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2022-2024 are available for download. Segment mix reveals concentration and diversification trends.

VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.

LBRX Revenue Over Time (2022–2024)